Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
Jun '22
|
Lord Sugar
|
|
Acl / NMS:ACLX |
£17.47
|
£76.42
|
337.44%
|
£306,204.93
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Candel Therapeutics / NGM:CADL |
£1.40
|
£4.84
|
245.71%
|
£242,000.01
|
May '22
|
Lord Reay
|
|
Novo Nordisk As / NYQ:NVO |
£56.40
|
£140.80
|
149.67%
|
£174,767.27**
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Tg Therapeutics / NCM:TGTX |
£15.05
|
£32.04
|
112.89%
|
£149,023.26
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Fortress Biotech / NCM:FBIO |
£1.92
|
£3.44
|
79.17%
|
£125,416.67
|
Apr '21
|
Baroness Deech
|
|
Novo Nordisk As / NYQ:NVO |
£36.35
|
£58.20
|
60.11%
|
£112,077.04
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Mustang Bio / NCM:MBIO |
£1.04
|
£1.61
|
54.81%
|
£108,365.39
|
May '22
|
Lord Triesman
|
|
Blue / NMS:BLUE |
£3.39
|
£4.97
|
46.61%
|
£102,625.36
|
Dec '22
|
Lord Hintze
|
|
Atai Life Sciences / NGM:ATAI |
£3.48
|
£4.61
|
32.47%
|
£92,729.89
|
Nov '21
|
Lord Sherbourne of Didsbury
|
|
Novo Nordisk As / NYQ:NVO |
£56.71
|
£70.73
|
24.73%
|
£87,313.29**
|
Mar '24
|
Lord Petitgas
|
|
Royalty Pharma / NMS:RPRX |
£30.08
|
£35.64
|
18.48%
|
£82,938.83
|
Jul '25
|
Lord Fink
|
|
Avacta Group / LSE:AVCT.L |
£51.50
|
£52.00
|
0.97%
|
£70,679.61
|
Apr '22
|
Lord Hylton
|
|
Genus / LSE:GNS.L |
£2,678.00
|
£2,520.00
|
-5.90%
|
£65,870.05
|
Jan '21
|
Lord Spencer of Alresford
|
|
Immupharma / LSE:IMM.L |
£12.65
|
£11.50
|
-9.09%
|
£63,636.36
|
Mar '14
|
Lord Glendonbrook
|
|
Bb Biotech / EBS:BION.SW |
£33.36
|
£27.20
|
-18.47%
|
£57,074.34**
|
Jun '16
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£47.80
|
£35.75
|
-25.21%
|
£52,353.56
|
Nov '24
|
Lord Moynihan of Chelsea
|
|
Sab Biotherapeutics / NCM:SABS |
£3.95
|
£2.58
|
-34.68%
|
£45,721.52
|
Mar '17
|
Lord Lloyd-Webber
|
|
Bb Biotech / EBS:BION.SW |
£54.95
|
£35.75
|
-34.94%
|
£45,541.40
|
Nov '23
|
Lord Mance
|
|
Novo Nordisk As / NYQ:NVO |
£101.69
|
£58.20
|
-42.77%
|
£40,062.94
|
Apr '24
|
Lord Grabiner
|
|
Novo Nordisk As / NYQ:NVO |
£127.46
|
£64.73
|
-49.22%
|
£35,549.19**
|
Apr '22
|
Lord Spencer of Alresford
|
|
Oxford Nanopore / LSE:ONT.L |
£320.00
|
£162.30
|
-49.28%
|
£35,503.13
|
Apr '24
|
Lord Willoughby de Broke
|
|
Novo Nordisk As / NYQ:NVO |
£122.75
|
£58.20
|
-52.59%
|
£33,189.41
|
May '23
|
Lord Stevens of Ludgate
|
|
Avacta Group / LSE:AVCT.L |
£112.00
|
£52.00
|
-53.57%
|
£32,500.00
|
May '24
|
Lord Londesborough
|
|
Novo Nordisk As / NYQ:NVO |
£134.66
|
£58.20
|
-56.78%
|
£30,253.97
|
Aug '23
|
Lord Nash
|
|
Relay / NGM:RLAY |
£10.62
|
£4.09
|
-61.49%
|
£26,958.57
|
Sep '21
|
Lord Darzi of Denham
|
|
Oxford Nanopore / LSE:ONT.L |
£612.60
|
£162.30
|
-73.51%
|
£18,545.54
|
Mar '24
|
Lord Petitgas
|
|
Moderna / NMS:MRNA |
£111.98
|
£25.00
|
-77.67%
|
£15,627.79
|
Oct '15
|
Lord Hayward
|
|
Sage / NGM:SAGE |
£46.11
|
£8.68
|
-81.18%
|
£13,177.19
|
May '11
|
Lord Glendonbrook
|
|
Mesoblast / NMS:MESO |
£101.20
|
£15.07
|
-85.11%
|
£10,423.91
|
May '20
|
Lord Wolfson of Aspley Guise
|
|
Adc Therapeutics / NYQ:ADCT |
£30.00
|
£3.25
|
-89.17%
|
£7,583.33
|
Apr '19
|
Lord Nash
|
|
Eq / NCM:EQ |
£8.20
|
£0.69
|
-91.59%
|
£5,890.24**
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Avenue Therapeutics / NCM:ATXI |
£12.00
|
£0.86
|
-92.87%
|
£4,987.50
|
Mar '24
|
Lord Moynihan of Chelsea
|
|
Adaptimmune / NMS:ADAP |
£1.47
|
£0.08
|
-94.49%
|
£3,857.14
|
Mar '23
|
Baroness Shields
|
|
Benevolentai / AMS:BAI.AS |
£2.46
|
£0.09
|
-96.14%
|
£2,703.25**
|
Dec '22
|
Lord Hintze
|
|
Affimed / NGM:AFMD |
£21.20
|
£0.00
|
-100.00%
|
£0.33
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.